A New Wave of Hope
Join Us in the Quest to Help Advance Treatment for Dravet Syndrome
A clinical study to potentially help reduce the number of seizures in children and adults with Dravet Syndrome.
See If Your Loved One Qualifies for This Study
Fill out the form below to help determine eligibility.
Who Can Take Part?
Eligible participants include individuals aged 2 to 65 who have been diagnosed with Dravet Syndrome and experienced the onset of seizures between the ages of 12 and 19 months. Additionally, they have experienced an average of four seizures per month over the past three months.
Participants who may qualify to join:
- Have been diagnosed with Dravet Syndrome.
- Are between the ages of 2 and 65 years old.
- Have experienced seizure onset between 12 and 19 months of age.
- Have had an average of 4 seizures per month during the last 3 months.
- Are willing and able or have a caregiver who can maintain study diaries throughout the DEEp SEA study.
Additional study requirements and exclusions may apply including certain anti-seizure medications. Only a qualified healthcare professional can determine if your loved one is eligible to participate in the study.
What to Expect During the DEEp SEA Study?
Screening
Screening
Study Treatment
Eligible participants will take part in a 15-week study treatment period. Participants will be randomly assigned to receive a liquid formulation of either the investigational drug or placebo. The placebo will look and taste like the investigational drug being tested in the clinical study but has no active ingredients in it.
During the study, participants can expect at least 6 on-site visits for tests and evaluations as well as 3 telephone visits to review progress. Participants or caregivers will need to maintain electronic diaries throughout the study.
Study Treatment
Eligible participants will take part in a 15-week study treatment period. Participants will be randomly assigned to receive a liquid formulation of either the investigational drug or placebo. The placebo will look and taste like the investigational drug being tested in the clinical study but has no active ingredients in it.
During the study, participants can expect at least 6 on-site visits for tests and evaluations as well as 3 telephone visits to review progress. Participants or caregivers will need to maintain electronic diaries throughout the study.
Open-Label Extension
Participants who complete the last visit of the study treatment period can continue in an open-label extension study (OLE). During the OLE, all participants will receive the investigational drug.